United Therapeutics (UTHR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$565.72-7.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · UTHR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -4.9% |
| Our one-year growth estimate | diamond | 9.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 14.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
UTHR — earnings miss
Dated 2026-11-04
Results of Operations and Financial Condition. On November 4, 2026, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
Why it matters: Management named this as a possible growth driver. Approval would open a new use for the drug.
Watch forFDA approves Nebulized Tyvaso for IPF by the end of 2027.
Also watch forFDA rejects the filing, asks for more study, or has not acted by the end of 2027.
Why it matters: The ASR is due to settle in Q4 2026. Settlement will show the final share count and any cash due to Citi.
Watch forUTHR reports final ASR settlement in Q4 2026 with no cash payment to Citi.
Also watch forSettlement slips beyond Q4 2026 or UTHR must pay cash to Citi.
Why it matters: Tyvaso DPI sales rose 4% year over year in Q2. Nebulized Tyvaso sales fell 18%, so DPI growth may help offset pressure elsewhere.
Watch forQ3 Tyvaso DPI sales exceed $326.6 million and grow year over year.
Also watch forQ3 Tyvaso DPI sales fall below $326.6 million or decline year over year.
Why it matters: Q2 revenue fell 2% from a year earlier. Growth would show the business is regaining pace.
Watch forQ3 total revenue tops $798.6 million, the Q3 2025 level.
Also watch forQ3 total revenue is below $798.6 million and falls year over year again.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$110 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $247 loss on $10,000 · 2.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,087 loss on $10,000 · 20.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Management said the filing could support a major growth step. An FDA decision will test that plan.
Watch forFDA approves ralinepag tablets for PAH by the end of 2027.
Also watch forFDA rejects the filing, asks for more study, or has not acted by the end of 2027.
Why it matters: The settlement aims to resolve pending patent cases with a competitor. Court action will show whether those cases are settled.
Watch forCourt records show the settlement ends the pending UTHR-Liquidia cases.
Also watch forCourt records show the settlement failed or the cases remain active.